Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImMI: Monobenzone and Imiquimod Creams with Standard Treatment in Advanced or Metastatic Melanoma
2024-520052-19-04Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of monobenzone and imiquimod in melanoma, sponsored by Amsterdam University Medical Center. Planned start Sep 2026; status: authorised.
02
Drugs
monobenzoneimiquimod
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-520052-19-04.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520052-19-04.